Traders should monitor for FDA decision by September 27, 2026; approval would position PRAX as a commercial-stage CNS biotech with first-mover advantage in precision epilepsy. The Pediatric Review Voucher could be monetized for hundreds of millions, providing non-dilutive capital. Consider positioning ahead of the PDUFA date, especially if regulatory signals remain positive.
Price Chart
Executive Summary
Praxis Precision Medicines announced FDA acceptance of its NDA for relutrigine, a first-in-class therapy for SCN2A and SCN8A developmental and epileptic encephalopathies, with a PDUFA target action date of September 27, 2026. The filing is supported by strong Phase 2 data showing robust seizure reduction, and the drug has multiple expedited designations including Breakthrough Therapy and Rare Pediatric Disease Designation.
Key Facts
- FDA accepted NDA for relutrigine with priority review and PDUFA date of September 27, 2026
- Relutrigine is first potential disease-modifying therapy for SCN2A/SCN8A DEEs, which currently have no approved targeted treatments
- NDA supported by positive interim results from EMBOLD study, stopped early for efficacy
- Relutrigine has Orphan Drug, Rare Pediatric Disease, and Breakthrough Therapy Designations
- If approved, eligible for Pediatric Review Voucher, enhancing commercial value
Financial Impact
High commercial and strategic value; potential first-in-class approval in ultra-rare pediatric epilepsy with voucher eligibility
Risk Factors
- FDA may not approve relutrigine despite priority review
- Safety or manufacturing issues could delay or block approval
- Commercial uptake may be limited by ultra-rare indication size
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3264996 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 29, 2026 13w ago | 8-K | $334.79 $282.12 | ▲ +15.73% | ▲ +18.55% | $292.66 (+12.58%) |
Jun 11, 2026 16w ago | Institutional Cluster | $247.98 $351.81 | ▲ +41.87% | ▲ +37.47% | $292.66 (+18.02%) |
Jun 2, 2026 17w ago | Press Release | $278.93 $367.85 | ▲ +31.88% | ▲ +29.38% | $292.66 (+4.92%) |
May 7, 2026 21w ago | Press Release | $333.28 $305.51 | ▼ −8.33% | ▼ −12.17% | $292.66 (−12.19%) |
May 4, 2026 21w ago | Press Release | $333.30 $307.75 | ▼ −7.67% | ▼ −10.41% | $292.66 (−12.19%) |
Apr 14, 2026 24w ago | Press Release | $343.60 $333.12 | ▼ −3.05% | ▼ −11.57% | $292.66 (−14.83%) |
Apr 6, 2026 25w ago | Press Release | $310.11 $319.60 | ▲ +3.06% | ▼ −10.41% | $292.66 (−5.63%) |
Mar 30, 2026 26w ago | Press Release | $322.19 $327.79 | ▲ +1.74% | ▼ −10.64% | $292.66 (−9.17%) |
Feb 28, 2026 30w ago | Institutional Cluster | $330.59 $350.60 | ▲ +6.05% | ▼ −3.27% | $292.66 (−11.47%) |
Feb 28, 2026 30w ago | Institutional Cluster | $330.59 $350.60 | ▲ +6.05% | ▼ −3.27% | $292.66 (−11.47%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access